The immunoblocking between PD-1 and activated cytotoxic T lymphocytes (CTLs), and between PD-L1 and tumor cells, has exhibited significant clinical efficacy in different types of cancer and was currently approved for treating tumors, including advanced stage of NSCLC [13]. The gene discussed is PDCD1; the disease is neoplasm.